Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
UNIVERSITE DE POITIERS has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are consolidated within 1 distinct art unit, reflecting a specific area of research or development. The presence of 2 pending office actions indicates that the university is actively pursuing patent protection for its biological or pharmaceutical innovations.
The university's portfolio is handled by 2 distinct examiners, ensuring that each application is reviewed by a different individual. GULLEDGE, BRIAN M is the busiest examiner for the institution, with 1 pending office action currently assigned. The use of 2 distinct examiners for 2 pending office actions within a single art unit provides a balanced prosecution environment for the university's innovations. This allows for multiple perspectives on the research within the Biotechnology & Pharmaceuticals sector.
For practitioners, the concentration in 1 distinct art unit means the technical subject matter is being evaluated by a single specialized group. However, the involvement of 2 distinct examiners, including GULLEDGE, BRIAN M, means that prosecution strategies must account for individual examiner preferences. This structure ensures that the university's pharmaceutical filings are thoroughly vetted by multiple experts within the same technical field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GULLEDGE, BRIAN M | 1 | 55.8% | +26.1% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18727787 | A COMPOSITION COMPRISING LIPID NANOPARTICLES AND AN ANTIFUNGAL POLYENE | GULLEDGE, BRIAN M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18727787 | A COMPOSITION COMPRISING LIPID NANOPARTICLES AND AN ANTIFUNGAL POLYENE | GULLEDGE, BRIAN M | — |
| 18692318 | VECTORS TARGETING BETA-D-N-ACETYLGLUCOSAMINIDASE | NIEBAUER, RONALD T | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18727787 | A COMPOSITION COMPRISING LIPID NANOPARTICLES AND AN ANTIFUNGAL POLYENE | GULLEDGE, BRIAN M | 1699 | §103§112 | Final Rejection | — | Pending | Jul 10, 2024 |
| 18692318 | VECTORS TARGETING BETA-D-N-ACETYLGLUCOSAMINIDASE | NIEBAUER, RONALD T | — | §103§112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial